[Lung transplantation]

Rev Prat. 2007 Feb 15;57(3):294-8.
[Article in French]

Abstract

Lung transplantation is now an effective therapy for patients of less than 60 years-old with chronic end-stage lung diseases which life expectancy is less than 12 to18 months in spite of maximal medical therapy. The various surgical procedures (single or bilateral lung or heart-lung transplantation) offer an adapted solution to all the candidates whatever the cause of the respiratory disease. The early postoperative mortality is less than 10% and the survival rates regularly improve and reach 65 to 7% at 3 years and more than 50% at 5 years for experienced programmes. Primary graft dysfunction, infections and airways complications are the main causes of early morbidity. Bronchiolitis obliterans is the main limiting factor of the long-term survival. Malignancies and drug toxicity, such as renal or vascular complications, occur also at that time.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Age Factors
  • Bronchiolitis Obliterans / etiology
  • France
  • Graft Rejection / etiology
  • Heart-Lung Transplantation
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Lung Diseases / surgery
  • Lung Neoplasms / etiology
  • Lung Transplantation* / physiology
  • Middle Aged
  • Patient Selection
  • Postoperative Complications
  • Surgical Wound Infection / etiology
  • Survival Rate

Substances

  • Immunosuppressive Agents